{
    "id": "ab2b37b1-2e0c-4d70-bc3d-c1469af68fd3",
    "indications": "xcopri indicated treatment partial-onset seizures adult patients .",
    "contraindications": "recommended initial xcopri 12.5 mg daily , titrated recommended maintenance 200 mg daily . recommended titration schedule exceeded . maximum 400 mg daily . ( 2.1 ) hepatic impairment : patients mild moderate hepatic impairment , maximum recommended 200 mg daily . ( 2.2 , 8.7 , 12.3 ) xcopri taken whole tablets crushed . crushed tablet mixed water either administered mouth oral suspension administered via nasogastric tube . ( 2.3 )",
    "adverseReactions": "xcopri contraindicated patients : hypersensitivity cenobamate inactive ingredients xcopri [ ( 5.1 ) description ( 11 ) ] familial short qt syndrome [ ( 5.2 ) ]",
    "ingredients": [
        {
            "name": "CENOBAMATE",
            "code": "P85X70RZWS"
        }
    ],
    "organization": "SK Life Science, Inc.",
    "name": "Xcopri",
    "effectiveTime": "20250430",
    "indications_original": "XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.",
    "contraindications_original": "The recommended initial dosage of XCOPRI is 12.5 mg once daily, titrated to the recommended maintenance dosage of 200 mg once daily.  The recommended titration schedule should not be exceeded.  The maximum dosage is 400 mg once daily. ( 2.1 ) Hepatic impairment: For patients with mild or moderate hepatic impairment, the maximum recommended dosage is 200 mg once daily.  ( 2.2 , 8.7 , 12.3 ) XCOPRI can be taken whole or the tablets can be crushed. The crushed tablet can be mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube. ( 2.3 )",
    "adverseReactions_original": "XCOPRI is contraindicated in patients with:\n                  \n                     Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI [see Warnings and Precautions (5.1) and Description (11)]\n                     \n                     Familial Short QT syndrome [see Warnings and Precautions (5.2)]"
}